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The anatomical routes for the clearance of cerebrospinal fluid (CSF) remain incompletely 47 
understood. However, recent evidence has given strong support for routes leading to 48 
lymphatic vessels. A current debate centers upon the routes through which CSF can 49 
access lymphatics, with evidence emerging for either direct routes to meningeal 50 
lymphatics or along cranial nerves to reach lymphatics outside the skull. Here,  a method 51 
was established to infuse contrast agent into the ventricles using indwelling cannulae 52 
during imaging of mice at 2 and 12 months of age by magnetic resonance imaging. As 53 
expected, a significant decline in overall CSF turnover was found with aging. 54 
Quantifications demonstrated that the bulk of the contrast agent flowed from the ventricles 55 
to the subarachnoid space in the basal cisterns. Comparatively little contrast agent signal 56 
was found at the dorsal aspect of the skull. The imaging dynamics from the two cohorts 57 
revealed that the contrast agent cleared from the cranium through the cribriform plate to 58 
the nasopharyngeal lymphatics. On decalcified sections, we confirmed that fluorescently-59 
labeled ovalbumin drains through the cribriform plate and can be found within lymphatics 60 
surrounding the nasopharynx. In conclusion, routes leading to nasopharyngeal 61 
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Cerebrospinal fluid (CSF) is produced within the ventricles by the choroid plexuses and 91 
circulates within the subarachnoid spaces around the brain and spinal cord. Historically, 92 
it was concluded that CSF would leave the central nervous system (CNS) via direct 93 
pathways through outcroppings of arachnoid tissue into the venous sinuses of the dura 94 
mater (1, 2). However, in recent decades it has become commonly accepted that 95 
lymphatic vessels play a significant role in the process of CSF drainage (3-6). Recent 96 
studies in rodents have demonstrated that lymphatic vessels appear to be the exclusive 97 
clearance route for tracers injected into the CSF, even for small molecular weight solutes 98 
(7, 8). An active area of research has focused upon the anatomical routes of outflow that 99 
CSF takes to access the lymphatic vessels. Support exists for access of CSF to lymphatic 100 
vessels that have been recently rediscovered in the dura mater (9-11) and for efflux along 101 
cranial or spinal nerves to reach extracranial lymphatics (7, 12-15). Of the perineural 102 
routes, evidence in many different species exists for routes along olfactory nerves through 103 
the cribriform plate (5, 10, 16-20).        104 
 105 
Imaging techniques have long been utilized to assess CSF outflow of tracers (6). 106 
Traditionally, these techniques have employed X-ray or scintigraphic measurements (21, 107 
22). Recently, two-photon or near-infrared fluorescence techniques (7-9, 13, 14, 23) have 108 
been developed to allow sensitive in vivo readouts within the CNS (imaging through-skull 109 
or through-spine), to specific efflux pathways (imaging through vomeronasal bones into 110 
the nasal region or imaging of lymphatic vessels draining to the superficial cervical or 111 
mandibular lymph nodes) or as a readout for transport to blood from multiple pathways. 112 
However, these methods can only allow assessments at one particular region at a 113 
relatively superficial level. On the other hand, contrast enhanced-magnetic resonance 114 
imaging (CE-MRI) techniques have the advantage of 3D imaging of the entire cranial or 115 
spinal regions in the context of the surrounding soft-tissue anatomy, with sufficient 116 
temporal resolution to track the dynamics of contrast agent outflow, and have a more 117 
immediate translational potential to the clinic (8, 11-13, 15, 24). 118 
 119 
One valid criticism of tracer injection studies is that they may inherently introduce artifacts 120 
due to relatively large acute volumes introduced into the CSF. In the mouse, with an 121 
estimated CSF volume of 35 µL (2), injections of 5 to 10 µL made within a short period 122 
likely introduce elevated pressure conditions that will affect the dynamics and routes of 123 
outflow (8, 25). Our group has attempted to address this issue by establishment of an 124 
indwelling cannula into the lateral ventricle of mice that allows slow infusion during 125 
imaging acquisition (13) at rates below the published rates for CSF production (2, 26). 126 
We have utilized this cannula system to allow MRI measurements of spinal CSF 127 
distribution and sacral outflow during the infusion of contrast agent (13). Similar cisterna 128 
magna infusion setups have also recently been employed by other groups to examine 129 
cranial CSF distribution (12, 15).        130 
 131 
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Alterations in CSF circulation may have significant effects on the pathogenesis of 132 
neurological conditions associated with the aging process, including dementia and stroke. 133 
Many research groups have now demonstrated that a slower overall efflux of CSF occurs 134 
during the aging process (7, 11, 14). Thus, we have utilized this expected difference in 135 
CSF turnover dynamics between younger (2-3 month old) and older (12 month old) mice 136 
to aid in validation of MRI quantifications. Second, we have investigated potential efflux 137 
routes by analyzing the contrast agent signal dynamics at several different locations 138 
within the CNS and the draining cranial lymph nodes. We hypothesized that differences 139 
in signal dynamics quantified between the two age groups will be apparent only at the 140 





Tracer infused into the lateral ventricle follows a continuous outflow route from the 146 
nasal cavity to the draining cervical lymph nodes  147 
  148 
Since CSF is principally produced by the choroid plexuses that are located in the 149 
ventricles, we decided to analyze the flow of tracer following an intraventricular low-rate 150 
infusion of a 17 kDa dendritic gadolinium-based contrast agent, Gadospin D (Fig. 1a). We 151 
chose Gadospin D rather than a low molecular weight contrast agent to limit potential 152 
diffusion into the brain parenchyma from the ventricular injection site. After stereotactic 153 
implantation of an indwelling cannula in the right lateral ventricle, mice were positioned in 154 
a prone position on a horizontal MRI platform. A polyethylene line filled with contrast agent 155 
was subsequently connected at one end to the cannula and at the other end to an infusion 156 
pump. After a baseline pre-contrast scan, an infusion of the contrast agent was started at 157 
a rate of 0.1 µl/min for 60 min and a series of CE-MRI images were collected over the 158 
course of 90 min. This experimental setup allowed us acquire images of the animal 159 
throughout the course of the infusion of a macromolecular contrast agent at rates not 160 
excessive to physiological levels.  161 
 162 
We first determined the general pattern of the spread of Gadospin D by generating 163 
maximum intensity projection images at each timepoint to allow a 3D dynamic 164 
visualization of the contrast agent (Video 1). An initial filling of the ventricular system was 165 
apparent with spreading ventrally to the basal cisterns and under the olfactory bulbs within 166 
the first 15 min after the start of the infusion. With increasing time, it was observable that 167 
the signal intensity of the tracers was progressively detectable in the nasal cavity, in the 168 
nasopharyngeal region and in the deep and superficial lymph nodes (Fig. 1b). Moreover, 169 
as observable in Fig. 1c and Video 1, it was possible to identify a continuous anatomic 170 
route along the nasopharynx that emerged from the nasal cavity and connected to the 171 
deep cervical lymph nodes. Connections also were apparent from the deep cervical 172 
lymphatics to the superficial cervical (or mandibular) lymph nodes, as previously shown 173 
using near-infrared imaging (7).  174 
 175 
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Reduced tracer clearance from the ventricles and slower efflux to draining lymph 176 
nodes in older mice 177 
 178 
It has recently been demonstrated that CSF production and drainage are both reduced in 179 
aged mice suggesting that the overall CSF turnover is slower with aging (7, 14, 27). 180 
During and immediately after the low-rate intraventricular infusion, we investigated the 181 
clearance of Gadospin D from the ventricular system in two groups of mice of either 2-3 182 
months (n=7) or 12 months of age (n=6). While the low rate infusion of contrast agent 183 
took place during the first 60 min, we observed that the signal intensity in the contralateral 184 
ventricles reached a peak at around 40 min and then progressively decreased in both 185 
age groups (Fig. 2a; Supp Fig.1a). At later timepoints, we could observe significantly 186 
stronger decreased signal intensity in the contralateral ventricle of the group of younger 187 
mice. As no significant difference was observed in the volume of the contralateral 188 
ventricles (Fig. 2b) between the two groups, we concluded that a decrease in the rate of 189 
CSF turnover is responsible for the reduced contrast agent clearance observed in the 12 190 
month old mice. 191 
 192 
Our previous studies have shown that lymphatic outflow from CSF is reduced in 18 month 193 
old mice compared to 2 month old mice following a bolus injection of a macromolecular 194 
fluorescently-labeled tracer (7). We tested whether this difference would be apparent by 195 
MRI in mice of 12 months of age by quantifying the signal intensity of the contrast agent 196 
in regions-of-interest (ROIs) positioned in the deep and superficial cervical lymph nodes. 197 
Dynamic CE-MRI quantification revealed less contrast agent signal in both groups of 198 
cervical lymph nodes in the 12 month old mice compared to the group of younger mice 199 
(Fig. 2c,d; Supp Fig.1b,c). Quantifications of the volume of 3D reconstructions of the 200 
cervical lymph nodes also did not show significant differences between the two age 201 
groups (Supp Fig.1d,e).  202 
   203 
In sum, we observed that with aging, a low-rate infusion of a macromolecular contrast 204 
agent is associated with reduced clearance from the ventricles and a delayed transport 205 
to draining lymph nodes which is consistent with previous studies by our group and others. 206 
Thus, we next aimed to exploit these differences in CSF turnover dynamics between the 207 
two age groups of mice to help identify the major efflux routes from the ventricular system 208 
to the lymphatic system. 209 
 210 
Contrast agent flows along the ventral aspect of the brain and down the spine  211 
 212 
CSF has recently been proposed to reach the dura mater on the dorsal aspect of the skull 213 
where it is hypothesized to be either directly or indirectly drained by meningeal lymphatic 214 
vessels leading to the deep cervical lymph nodes (9, 28-30). Previous work has 215 
highlighted lymphatic vessels in the dural tissue surrounding the sagittal and the 216 
transverse sinuses to be “hotspots” for uptake from the CSF. Thus, following 217 
intraventricular infusion of Gadospin D, we quantified the signal intensity in two ROIs of 218 
the dorsal aspect of the skull in proximity to these regions. In both areas, we could 219 
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observe only a limited maximum change in signal intensity compared to baseline (sagittal 220 
sinus ROI: <42%; quadrigeminal cistern ROI: < 120%) and no significant differences at 221 
any timepoint between the groups of 2 month and 12 month old mice (Fig 3 a,b,c; Supp 222 
Fig.2 a,b). 223 
 224 
On the other hand, quantifications of ROIs in the ventral region (at the basal cisterns 225 
around the circle of Willis and the internal carotid artery) show a substantial increase in 226 
maximum change in signal intensity compared to baseline (CoW ROI: >700%; Internal 227 
carotid ROI: >700% ) suggesting that this area is the major site of contrast agent bulk flow 228 
(Fig 3 a,d,e; Supp Fig.2 c,d). Moreover, in the two regions investigated the signal intensity 229 
was significantly quantitatively higher at earlier time points in young mice compared to 230 
the group of 12 month old mice. These results indicate that an infused macromolecular 231 
tracer principally flows with the CSF through the ventral, rather than dorsal, aspect of the 232 
skull.  233 
 234 
As CSF leaving the ventricles has free communication with the subarachnoid space 235 
around the spinal cord, we also quantified the dynamics in the ventral aspect of the 236 
cervical spine (Supp Fig.3a). We observed a rapid increase in signal intensity in the group 237 
of young mice that reached a maximum percentage change of more than 600%. 238 
Conversely, in the group of 12 month old mice, the signal intensity increase was delayed 239 
and only reached approximately half ot the value observed in young mice. Thus, CSF 240 
tracer flow from the ventricular system to the spine can be easily demonstrated with CE-241 
MRI and exhibits the expected decline with aging. 242 
 243 
Recent work has introduced the concept of glymphatic flow that would theoretically aid in 244 
CSF/solute penetration into the brain parenchyma along paraarterial spaces. Recent MRI 245 
studies have shown that low molecular weight contrast agents, such as gadoteric acid 246 
(Gd-DOTA), do indeed demonstrate signal enhancement within the parenchyma (31-36). 247 
However, we were unable to confirm a significant influx of the Gadospin D contrast agent 248 
(17 kDa) into the brain cortex in either group (maximum percentage change of 17%). This 249 
limited signal enhancement of a macromolecular contrast agent within the brain is 250 
consistent with our earlier study (8) and others (12).  251 
 252 
Thus, we conclude from this study that bulk flow routes to the basal cisterns and the 253 
subarachnoid space of the spinal canal are the major pathways for CSF macromolecular 254 
distribution from the ventricular system. 255 
 256 
Dynamics of CSF contrast agent outflow support route(s) leading to the 257 
nasopharyngeal lymphatics 258 
 259 
After observing that a significant portion of the tracer reaches the basal cisterns, we aimed 260 
to elucidate the potential anatomical pathways from this location that might be used to 261 
reach the cervical draining lymph nodes. Based on our observation that the bulk of the 262 
contrast agent appeared to flow continuously from the region of the olfactory bulbs to the 263 
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nasopharynx and to the draining lymph nodes, we first quantified the changes in signal 264 
intensity in ROIs localized in the nasal turbinates and the nasopharynx (Fig 4 a,b,c; Supp 265 
Fig.4 a,b). Dynamic imaging showed in the group of 12 month old mice, a delayed and 266 
significantly reduced transport of contrast agent in these two regions.  267 
 268 
At other regions suggested to be efflux sites from the skull, CSF contrast agent signal 269 
could be detected in the jugular region below the skull and around the optic nerves (Fig 270 
4 a,d,e; Supp Fig.4 c,d). However, at these two regions, our quantifications revealed that 271 
no significant differences in the signal intensity at any time point were observed between 272 
the young and 12 month old groups. In fact, the jugular region appeared to show a trend 273 
towards increased signal intensity over time in the 12 month old mice compared to the 274 
young mice indicating that this region may be a site of accumulation of contrast agent. An 275 
earlier report has shown that dural lymphatic vessels of this region become more 276 
hyperplastic with age (11).  277 
 278 
Thus, as the expected differences in signal dynamics between young and older animals 279 
were only detectable in the nasal turbinate and the nasopharyngeal areas, we conclude 280 
that this route is one of the major pathways for CSF clearance from the cranium to the 281 
cervical lymph nodes. 282 
 283 
Histological confirmation of CSF outflow route(s) to the nasopharyngeal 284 
lymphatics 285 
 286 
Interestingly, the signal quantifications revealed that only a minimal increase of signal 287 
(170% in young mice, 85% in 12 month old mice) could be detected within the turbinates 288 
themselves in either group, whereas much larger signal increases were detected at the 289 
nasopharynx (710% in young mice, 570% in 12 month old mice). This may suggest that 290 
the contrast agent distributes to a large area throughout the nasal cavity after effluxing 291 
through the cribriform plate before draining to the lymphatic vessels near the nasopharynx 292 
leading to the lymph nodes, as appears to be evident from the sagittal view in Video 1.  293 
 294 
To further evaluate how CSF tracers drain through the cribriform plate to reach lymphatics 295 
surrounding the nasopharynx, we have injected AlexaFluor647-labeled ovalbumin 296 
(AF647-OVA) using the same slow infusion protocol employed within the MRI and have 297 
assessed the presence of tracer on sections from decalcified craniums and deep cervical 298 
lymph nodes. Lymphatic vessels have been identified using LYVE-1 antibodies.  As seen 299 
in Figure 5a,b taken from two coronal sections at different levels of the nasal cavity, 300 
AF647-OVA is clearly associated with olfactory nerves crossing the cribriform plate and 301 
is distributed throughout a wide volume of nasal mucosal tissue. A rich network of LYVE1+ 302 
lymphatic vessels exists laterally on both sides of the nasopharynx and these vessels 303 
could be found containing AF647-OVA signal (Figure 5c-e). Deep cervical lymph nodes 304 
located downstream of this site also contained AF647-OVA that was found within LYVE-305 
1+ lymphatic sinuses (Figure 5f-j). Thus, this serves as histological confirmation of the 306 




In this study, we have assessed CSF outflow by MRI in two different age groups (2-3 310 
months and 12 months) of mice by utilizing an indwelling catheter system to allow low-311 
rate infusion of a macromolecular contrast agent during a series of image acquisitions. 312 
Similar to previous reports, we found slower dynamics of CSF circulation in the older 313 
cohort of mice compared to the younger mice. Imaging of the contrast agent dynamics in 314 
the cranial region revealed that the bulk of the CSF flowed ventrally under the brain 315 
through the basal cisterns and exited through the cribriform plate to be collected by 316 
lymphatics in the nasopharyngeal region.  317 
 318 
Our methods are similar to those within recent publications utilizing MRI for examination 319 
of CSF flow in rodents (11, 12, 15). In these studies, the authors infused contrast agents 320 
within the MRI into the cisterna magna through a cannula and examined the efflux routes 321 
from the cranial cavity. In our study, we chose to infuse into the ventricles, close to the 322 
source of production at the choroid plexuses, which allowed assessment of the clearance 323 
from the ventricular system, as well as distribution to and efflux from the subarachnoid 324 
space. 325 
 326 
We observed minimal contrast agent signal in the dorsal region near the dural sinuses or 327 
above the cortical hemispheres. Thus, this is contrary to a concept of a major pathway of 328 
CSF outflow at the dorsal dura, as proposed in several recent studies in mice (9, 28, 29) 329 
and recently extended to the human situation (37). Instead, the dynamics clearly indicated 330 
that the majority of contrast agent traversed the basal cisterns with pathways from the 331 
cisterna magna to the subarachnoid space around the circle of Willis. This is consistent 332 
with both historical data (1, 38) and other recent MRI studies (8, 11, 12, 15, 24, 33). While 333 
it is clear that some portion of CSF does reach the surface of the cortical hemispheres as 334 
well as the subarachnoid cisterns located near the dural sinuses (12, 13, 39, 40) the 335 
significance and ultimate egress route(s) for this flow remain open questions.  336 
 337 
As we anticipated, our data indicates that there is a reduction in CSF outflow in older mice 338 
consistent with previous reports (7, 11, 14, 41). We were able to detect delays in 12 339 
month-old animals in CSF clearance and transport at several locations along the CSF 340 
flow pathways, including the lateral ventricle, basal cisterns, cervical spinal subarachnoid 341 
space, nasal turbinates, nasopharyngeal lymphatics and CNS-draining lymph nodes. 342 
Thus, the data is indicative of an overall reduction in CSF turnover with aging. The reason 343 
for this diminished turnover of CSF is not yet clear, however, it may be related to a 344 
reduced CSF production by the choroid plexuses (27, 42), morphological changes in the 345 
dural lymphatics (11) or a reduced transport within lymphatic vessels outside the CNS 346 
(43-45). Whether this slowed CSF circulation plays a role in the development of 347 
neurodegenerative disorders associated with aging, as speculated in many recent studies 348 
(11, 46), remained to be determined.  349 
 350 
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We took advantage of the differences in contrast agent dynamics between the two 351 
different age groups of mice to attempt to elucidate the relative importance of several 352 
potential efflux routes. We hypothesized that only along the major bulk flow pathways for 353 
CSF egress would the patterns of contrast agent dynamics between the two age groups 354 
mirror those seen at the downstream lymph nodes. Since we found that limited contrast 355 
agent signal was apparent along the dorsal aspect of the skull, we focused these efforts 356 
on potential efflux routes from the basal cisterns. From this location, evidence exists in 357 
the literature for outflow to the lymphatic system through the cribriform plate (1, 5, 7, 16, 358 
17, 19, 47), along the sheaths surrounding the optic nerves (7, 48, 49), through the jugular 359 
foramina (7, 10, 11, 15, 47) and from the spinal column (13, 23, 50). Of these routes, in 360 
our study only the spinal and nasal regions appeared to exhibit the expected contrast 361 
enhancement dynamics between the two age groups of mice. An outflow pathway to the 362 
lymphatic system does indeed exist in rodents from the sacral region of the spine, 363 
however, our previous work and others have determined that under normal conditions the 364 
spinal pathways are minor compared to the cranial efflux routes (13, 51, 52). Thus, the 365 
resulting conclusion of a major CSF outflow pathway through the cribriform plate would 366 
be in agreement with many previous studies (14, 18, 53, 54). Strong supporting evidence 367 
for this conclusion comes from experiments blocking this pathway which resulted in 368 
dramatic decreases in tracer recovery outside the CNS and increased intracranial 369 
pressure during fluid challenge (53, 55). However, we cannot rule out at this point that 370 
more direct pathways may exist from the basal skull to reach the nasopharyngeal 371 
lymphatics.   372 
 373 
This conclusion appears to conflict with that of Ahn et al. in rats who determined using 374 
MRI imaging with a macromolecular constrast agent that basal meningeal lymphatic 375 
vessels draining through the jugular foramina are the major route for CSF macromolecular 376 
uptake and drainage. It must be noted that in their study Ahn et al. did not investigate any 377 
potential efflux through the cribriform plate region. However, another possible explanation 378 
for this discrepancy may be due to different experimental conditions between our study 379 
and Ahn et al. In a recent elegant MRI study by Stanton et al, the authors have 380 
demonstrated that the choice of anesthesia has a significant effect on the amount of efflux 381 
through the cribriform plate, with mice under isoflurane anesthesia demonstrating much 382 
less Gd-DTPA signal in this area (15). This study is consistent with earlier work 383 
demonstrating differences in CSF flow dynamics under different types of anaesthesia (8, 384 
13, 56). The authors demonstrated that mice under 1.5% anesthesia exhibited more 385 
signal at the jugular foramina along the cranial nerves and also to the spinal canal, 386 
indicating that shunting of the CSF flow may occur under certain conditions (15). This 387 
potential redirection of flow is an important factor to consider, especially in the context of 388 
pathological conditions such as hydrocephalus or glioblastoma, which may block CSF 389 
outflow pathways at the skull and reroute flow to the spine (57, 58). 390 
 391 
The situation in humans remains unresolved (6). Studies have presented evidence both 392 
for and against efflux of contrast agent through the cribriform plate (54, 59-61). One recent 393 
clinical MRI study has concluded that CSF efflux to the nasal region is minimal in humans 394 
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(61). This paper used a low molecular weight gadolinium contrast agent injected into the 395 
lumbar intrathecal space and examined the nasal turbinates at multiple timepoints in 396 
patients with various CSF disorders. Although contrast agent was observable in almost 397 
half the patients below the cribriform plate along the olfactory nerves, the authors were 398 
unable to observe a significant increase of signal within the nasal cavity at any time point. 399 
Our current study demonstrates the technical difficulty of detecting significant contrast 400 
agent signal enhancement within nasal tissue using an MRI approach, even though we 401 
employed a macromolecular contrast agent that should be expected to clear exclusively 402 
from the nasal submucosa through lymphatics (53). While the exact anatomical routes 403 
remain to be elucidated, it is evident from our decalcified sections after ovalbumin infusion 404 
that the contrast agent spreads throughout a wide volume of the nasal tissue after 405 
crossing the cribriform plate, which may partially account for the difficulty in detecting 406 
signal with MRI in humans.  407 
 408 
In sum, through establishment of a technique allowing dynamic CE-MRI under low-rate 409 
infusion of gadolinium contrast agents, we conclude that CSF distributes from the 410 
ventricles to the subarachnoid space ventral to the brain and in a caudal direction down 411 
the spine. Under our experimental conditions, a significant outflow route from the cranium 412 
appeared to be through the nasal region to reach lymphatic vessels near the nasopharynx 413 
before draining to the cervical lymph nodes. With aging, the dynamics of clearance from 414 
the ventricles and flow through the nasal tubinates and nasopharyngeal lymphatics to the 415 
lymph nodes were reduced. These experiments have set the stage for further MRI 416 





Female wild-type mice (Janvier, France) on the C57BL/6 background were kept under 422 
specific pathogen-free conditions until they were used for experimental studies.  423 
Surgical preparation 424 
Mice were anesthetized by intraperitoneal injection of 100 mg/kg ketamine and 20 mg/kg 425 
xylazine and fixed in a stereotaxic frame (Kopf Instruments, Tujunga, CA). Under this 426 
narcosis, the skull was thinned with a Proxxon GG 12 Engraving drill (Proxxon, Niersbach, 427 
Germany). A 28G, 2.5-mm-long MRI-compatible microcannula (#328OP/PK/Spc; Plastics 428 
One) was inserted stereotactically 0.95 mm lateral and 0.22 mm caudal to the bregma 429 
and 2.50 mm ventral to the skull surface (13). The microcannula was sealed with 430 
cyanoacrylate glue. Animals were transferred into the magnet in a prone position on an 431 
MRI cradle (BioSpec Avance III 94/20; Bruker Biospin GmbH, Ettlingen, Germany). A 1-432 
1.5m long polyethylene catheter filled with a Gadospin D (nanoPET Pharma GmbH, 433 
Germany) solution at a Gd concentration of 25 mM was connected to the MRI compatible 434 
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microcannula and a 10-µl syringe operated by an MRI compatible NanoJet syringe pump 435 
(Chemyx Inc., Stafford, TX, USA).  The skin incision was then closed with a medical 436 
adhesive bandage around the cannula and the catheter. Animals were allowed to breathe 437 
spontaneously during the entire experimental procedure. Respiratory rate and 438 
temperature were measured with non-invasive probes (SA Instruments, Stony Brook, 439 
NY). Throughout the experiment, the body temperature was maintained between 36.5°C 440 
and 37.5°C. During the course of the MRI measurement, the initial narcotic was 441 
supplemented as necessary with 0.5-1% isoflurane delivered in 98% O2 to keep the 442 
breathing rate lower than 140 breaths per min. 443 
Dynamic contrast-enhanced MRI of the head-neck 444 
Animals were examined in a horizontal-bore 9.4 T animal scanner (BioSpec Avance III 445 
94/20; Bruker Biospin GmbH, Ettlingen, Germany) with a BGA12S gradient system with 446 
ParaVision 6.0.1 (Bruker Biospin GmbH) and a linearly polarized coil with an inner 447 
diameter of 40 mm (Bruker Biospin GmbH). Contrast-enhanced imaging was achieved 448 
with a three-dimensional time of flight gradient recalled echo sequence (3D-TOF-GRE) 449 
originally adapted for imaging of peripheral lymph vessels (62) with a recovery time of 450 
12.0 ms, echo time = 2.5 ms, flip angle = 25o, a matrix of 600 × 432 × 180, field of view 451 
36.00 mm × 25.92 mm × 18.00 mm, 1 average and a scan time of 4 min 19 s 200 ms. A 452 
phantom placed in the vicinity of the animal's head (solution diluted in 0.9% NaCl at 5 mM 453 
gadolinium) was used for image intensity normalization over the time series. Following a 454 
pre-contrast scan, a Gadospin D solution at 25 mM Gd was infused at a constant rate of 455 
0.1 μl/min for 60 min. Total scan time was between 95 and 99 min. 456 
 457 
Data processing 458 
ROIs were manually drawn around the different anatomical regions investigated with 459 
Horos (version 3.3.6, Horos Project). Signal intensity was normalized using the reference 460 
phantom. The normalized ROI value (provided in the supplemental data) was calculated 461 
by dividing the original ROI value by the phantom value of the same scan. Contrast agent 462 
efflux over time was determined by calculating the percentage change of signal intensity 463 
as a function of time after infusion of the contrast agent using the following equation: 464 
[(normalized signal intensity – normalized pre-contrast intensity)/ (normalized pre-465 
contrast intensity)] × 100. Ventricle and lymph node volumes were quantified using semi-466 
automatic segmentation tools in 3DSlicer, version 4.11 (www.slicer.org). All the digital 467 
imaging and communications in medicine images were imported into 3D Slicer for the 468 
segmentation and 3D modelling. The region of interest was first defined and segmented 469 
with the segment editor module. The model maker module was used to create the 3D 470 
model. Finally, the volume was determined via the segment statistics module. 471 
 472 
Histological analysis of tracer efflux to lymphatics 473 
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For experiments where ventricular infusions were followed by histological analysis an 474 
identical procedure was used with the following modifications: a solution of ovalbumin-475 
Alexa647 (Thermo Fisher Scientific, Waltham, MA, USA) dissolved in artificial CSF 476 
(Harvard Apparatus, Holliston, MA, USA) at a concentration of 5 mg/mL was infused at a 477 
constant rate of 0.1 μL/min for 60 min; the 2-3 months wild-type mice were sacrificed at 478 
the end of the infusion. 479 
For decalcification, intracardiac perfusion with PBS and 4% PFA was performed. 480 
Afterwards, the mice were decapitated followed by the removal of skin, muscles, incisors 481 
and lower jaw from the cranium. The cranium was then immersed in 4% PFA for overnight 482 
fixation before being placed in 14% EDTA for 7 days (refreshed daily) at 4°C. Decalcified 483 
tissue was then immersed in 30% sucrose for 3 days for cryoprotection before OCT 484 
embedding. 20µm-thick coronal sections were cut from a cryostat (Cryostar NX50) and 485 
stored at -80°C. For immunofluorescence staining of LYVE-1, frozen tissues were first 486 
hydrated with PBS for 10 minutes, then permeabilized by 0.1% triton for 10 minutes. 10% 487 
goat serum was used for blocking for 1 hour at room temperature. Tissues were incubated 488 
with primary antibody (rabbit anti-Lyve-1, AngioBio, catalogue 11-034, 1:600 dilution) for 489 
3 hours at room temperature and then washed with PBS before incubating with secondary 490 
antibody (goat anti-rabbit Alexa488) for 2 hours at room temperature. Imaging of the nasal 491 
region was done under Zeiss Axiozoom V16 microscope equipped with a Photometrics 492 
PrimeBSI sCMOS camera combined with a LED illumination system pe-4000 and ZEN 2 493 
software (Carl Zeiss). Higher magnification images were then acquired using a Zeiss 494 
LSM800 confocal microscope.  495 
For processing of draining lymph nodes, cervical lymph nodes were post-fixed in 4% PFA 496 
at 4 °C overnight. Lymph nodes were further immersed in 30% sucrose for 2 days at 4 °C 497 
before being snap-frozen in melting isopentane with liquid nitrogen. The frozen tissue was 498 
cut serially into 15 µm sections with a cryostat microtome (Leica Microsystems, Wetzlar, 499 
Germany). Sections were incubated with an anti-LYVE-1 (eBioscience, San Diego,CA, 500 
USA, clone ALY7, 1:200) primary antibody for 2 hours at room temperature before 501 
incubation with a Donkey anti-rat (Invitrogen, Grand Island, NY, 1:1000) secondary 502 
antibody conjugated with Alexa488 for 1 hour at room temperature. Sections were finally 503 
counterstained with DAPI. Regions of interest were acquired with a Zeiss LSM 880 Axio 504 
Observer. 505 
Statistics 506 
Statistical analyses were performed with GraphPad Prism 5 (GraphPad). Graphs 507 
represent mean ± SEM. Means of two groups were compared using an unpaired two-508 
tailed Student’s t test. Two-way ANOVAs were used for comparison with time points being 509 
a within-subject factor and age being a between-subject factor, followed by Bonferroni’s 510 
posthoc test. A p-value <0.05 was considered statistically significant. 511 
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Figure 1: Dynamic CE-MRI shows continuous efflux of contrast agent from the nasal region through 689 
lymphatic vessels to cervical lymph nodes following low-rate ventricular infusion. A Schematic 690 
representation of the experimental setup. MRI-compatible cannulae were stereotactically implanted into the 691 
ventricle of 2-3 months old C57BL/6J mice anesthetized with ketamine/xylazine. The animals were then 692 
transferred into a horizontal-bore 9.4 T MRI. Polyethylene tubing containing the contrast agent (Gadospin 693 
D solution at 25 mM Gd) was attached connecting the cannula and the infusion pump.  Before tracer 694 
infusion, T1-weighted (3D time-of-flight gradient recalled echo sequence) MRI measurements were started 695 
and followed by intraventricular low-rate infusion (0.1 µl/min) of the tracer while MRI acquisitions continued. 696 
B Representative signal dynamics using maximum-intensity projections visualizing the entire head-neck 697 
region. Following the beginning of contrast agent infusion, enhancement of the signal intensity in the 698 
ventricle is detectable at 4 min, in the nasal cavity at 17 min, and in the neck lymph nodes at 30 and 60 699 
min. C Visualization of the spread of tracer after 90 min demonstrating continuous signal enhancement 700 
from the cribriform plate to the nasopharyngeal lymphatic vessels to cervical lymph nodes. Data are 701 
representative of n = 7 mice and three independent experiments. Scale bars: 3 mm. 702 
 703 












Figure 2: Clearance from ventricles and efflux to lymph nodes are reduced in 12 months old mice. 715 
Visualization of tracer spread after low-rate intraventricular infusion (0.1 µl/min) of a Gadospin D solution 716 
at 25 mM; data acquired with a series of T1-weighted MRI measurements (3D time-of-flight gradient 717 
recalled echo sequence). A Signal dynamics of Gadospin D contrast agent showing clearance from the 718 
contralateral-ventricles in the horizontal plane in 2-3 months and 12 months old mice. B Representative 719 
images of 3D reconstruction of the contralateral-ventricles of 2-3 months and 12 months old mice. Ventricle 720 
volumes of 2-3 months and 12 months old mice were compared with two-tailed Student’s t-test. C-D Signal 721 
dynamics in the horizontal plane of Gadospin D tracer efflux to deep and superficial cervical lymph nodes 722 
in 2-3 months and 12 months old mice. ROIs shown in yellow. Data are expressed as mean ± SEM of n= 723 
7 2-3 months old mice vs n=6 12 months old mice and are representative of three independent 724 















Figure 3: CSF predominantly clears along the ventral aspect of the skull. Visualization of tracer 739 
clearance after low-rate intraventricular infusion (0.1 µl/min) of Gadospin D solution at 25 mM Gd.  Data 740 
were acquired with a series of T1-weighted MRI measurements (3D time-of-flight gradient recalled echo 741 
sequence). A Overview scheme of ROI location. B,C Coronal sections demonstrating in 2-3 months and 742 
12 months old mice the dynamics of CSF efflux in representative ROIs (shown in yellow) of the dorsal 743 
aspect of the skull: in the perisagittal superior sinus and the quadrigeminal cisterns. D,E Horizontal sections 744 
showing the dynamic of CSF efflux in the ventral aspect of the skull in 2-3 months and 12 months old mice: 745 
around the circle of Willis and around the internal carotid (ROIs in yellow). Quantifications of the different 746 
ROIs are expressed as the mean ± SEM of n= 7 2-3 months old mice vs n=6 12 months old mice and are 747 
representative of three independent experiments. *p<0.05, (two-way ANOVA followed by Bonferroni’s 748 












Figure 4: Clearance of CSF from the cranium is reduced with aging in the nasal turbinates and the 760 
nasopharynx but not in the jugular region and around the optic nerves. Imaging of tracer clearance 761 
after low-rate intraventricular infusion (0.1 µl/min) of Gadospin D solution at 25 mM Gd.  Data were acquired 762 
with a series of T1-weighted MRI measurements (3D time-of-flight gradient recalled echo sequence). A 763 
Overview scheme of ROI location. B Horizontal sections demonstrating the dynamics of CSF efflux to nasal 764 
turbinates in 2-3 months and 12 months old mice. C Sagittal sections reveal the dynamics of contrast agent 765 
in the nasopharynx in the two groups of mice. D Coronal sections demonstrating the CSF efflux from the 766 
jugular region in the groups of mice of different ages. E Horizontal sections showing CSF efflux along the 767 
optic nerve in 2-3 months and 12 months old mice. Quantifications of the different ROIs (shown in yellow) 768 
are expressed as the mean ± SEM of n= 7 2-3 months old mice vs n=6 12 months old mice and are 769 
representative of three independent experiments. *p<0.05 (two-way ANOVA followed by Bonferroni’s 770 
posthoc test). Scale bars: 1 mm.  771 
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 772 
Figure 5: Histological validation of CSF tracer efflux through the cribriform plate to nasopharyngeal 773 
lymphatics and to deep cervical lymph nodes. Fluorescently-labeled ovalbumin (OVA) was introduced 774 
via low-rate intraventricular infusion (0.1 µl/min for 60 min) and at 90 min the mice were sacrificed for post-775 
mortem analysis of tracer efflux. A, B Coronal sections of decalcified skulls demonstrating significant efflux 776 
of OVA into the nasal mucosal tissues. OVA (purple) can be seen crossing the cribriform plate alongside 777 
several olfactory nerve bundles (indicated with *). Lymphatic vessels (stained with LYVE-1 in green) can 778 
be found in proximity to the nasopharynx under the nasal turbinates. C-E High-magnification view of the 779 
nasopharyngeal region indicated by the yellow box in B, demonstrating OVA signal within the LYVE-1+ 780 
lymphatic vessels. F, G Sections of deep cervical lymph nodes indicating close association of OVA signal 781 
within lymphatic sinuses stained with LYVE-1. H-J High-magnification view of the region indicated by the 782 
yellow box in F, demonstrating OVA signal within the LYVE-1+ lymphatic sinuses. Data are representative 783 
of n = 6 mice and two independent experiments. 784 
